Indocyanine Green Market Poised for Rapid Growth, Driven by Surgical and Ophthalmic Applications — Arizton Advisory & Intelligence

Event summary

The global indocyanine green (ICG) market was valued at USD 180 million in 2025 and is projected to reach USD 380 million by 2031, growing at a CAGR of 13.26%.
North America dominates the ICG market with a share of around 37% in 2025.
The solid form type segment accounted for the largest market share of around 69% in 2025.
Specialty clinics are expected to show significant growth, with the fastest CAGR of 14.17% from 2026 to 2031.

The big picture

The indocyanine green market is experiencing robust growth driven by the increasing adoption of minimally invasive and robotic-assisted surgeries, as well as the rising prevalence of retinal diseases. The strategic importance of ICG in modern surgical procedures and ophthalmic diagnostics positions it as a critical component in the evolution of precision medicine. Key players are embedding fluorescence imaging into next-generation surgical systems, reinforcing the market's competitive landscape.

What we're watching

Technological Integration: How the integration of ICG-based fluorescence imaging into robotic-assisted surgery platforms will affect market adoption and competitive dynamics.
Regional Expansion: Whether North America can sustain its leadership position as other regions, particularly APAC, invest in advanced surgical technologies.
Application Diversification: The pace at which ICG applications expand beyond ophthalmic angiography and fluorescence-guided surgery into other diagnostic and therapeutic areas.